Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis.
Chu Miow Lin
D
D
Mulleman
D
D
Azzopardi
N
N
Griffoul-Espitalier
I
I
Valat
J-P
JP
Paintaud
G
G
Goupille
P
P
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood*; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000097:blood*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab